The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations

Four studies using different daily doses (100 mg, 200 mg, 300 mg and 400 mg) have examined the bioequivalence of the once daily formulation metoprolol CR/ZOK and conventional metoprolol tablets (CT). These studies showed metoprolol CR/ZOK to have a similar beta 1-blocking activity to metoprolol CT but that the bioavailability of the new formulation was lower. This paper presents the analysis of data from all four studies, looking at the relationship between plasma concentrations and beta 1-blockade measured as reduction of exercise induced tachycardia. The log linear pharmacodynamic model was used for each of the four doses to compare the two formulations. Mean slopes and intercepts in the linear regression analysis of log plasma concentration of metoprolol versus beta 1-blockade did not differ significantly between CR/ZOK and CT in any of the four studies. After having shown lack of influence of the absorption rate of the plasma concentration-effect relationship, data for CR/ZOK and CT formulations from the 200 mg study were pooled for each individual subject and fitted to an Emax model. The maximal beta 1-blocking effect (Emax) was 28% (95% confidence interval: 25-31%) and the plasma concentration for obtaining 50% of Emax (C50) was 105 nmol/L (95% confidence interval: 74-135 nmol/L). The plasma concentration-effect data from the 100 mg, 300 mg and 400 mg studies were reasonably well within the 95% prediction interval based on the 200 mg study, which showed the validity of the obtained relationship.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. J Tangeman and J H. Patterson Extended-Release Metoprolol Succinate in Chronic Heart Failure Ann. Pharmacother., May 1, 2003; 37(5): 701 - 710. [Abstract] [Full Text] [PDF]

				B. A. Groenning, J. C. Nilsson, L. Sondergaard, T. Fritz-Hansen, H. B. W. Larsson, and P. R. Hildebrandt Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2072 - 2080. [Abstract] [Full Text] [PDF]

				L. Brynne, M. O. Karlsson, and L. K. Paalzow Concentration-Effect Relationship of l-Propranolol and Metoprolol in Spontaneous Hypertensive Rats after Exercise-Induced Tachycardia J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1152 - 1158. [Abstract] [Full Text]